# NIH Reporter #5R44CA310518-02

CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer

**Recipient:** EMBIOSYS INC.

**Award Amount:** $870,482.00
**Ceiling:** $870,482.00

**Awarded:** September 11, 2026

**Identifier:** 5R44CA310518-02

The National Cancer Institute awarded EMBIOSYS INC. $870,482 for a project developing a wearable, non-invasive device to deliver induced electric field therapy and assess its safety and efficacy in combination with standard treatment for triple-negative breast cancer.

### Description

Funding for research developing and evaluating a wearable device that delivers induced electric field therapy alongside standard chemotherapy for high-risk triple-negative breast cancer.

[View original record](https://reporter.nih.gov/search/J7l2tQ4hHkqRePwGq3m5kA/project-details/11418087)